Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors

NCT05142592 is registered in ClinicalTrials.gov with Nanjing Immunophage Biotech Co., Ltd as lead sponsor.

NCT NCT05142592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05142592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
November 15, 2021
Completion date
March 5, 2026
Enrollment
34 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, safety issues, tolerability